(GILD)

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an agg...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy® (sacituzu...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Evaluate the expected performance of Gilead (GILD) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for...

Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.25, denoting a +2% change from the preceding trading day.